We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comment: Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent.
- Authors
Gilbert, Brian W.; Reeder, Jacob A.
- Abstract
The article reviews the available clinical trial data for andexanet alfa and its role in clinical practice. Topics include use of prothrombin complex concentrate (PCC) should be delegated to an adjunct therapy to andexanet alfa-based on the relative paucity associated with its role in factors Xa (FXa) inhibitor reversal; no randomized controlled trial has been published to date evaluating PCC use in FXa inhibitor reversal, and ANNEXA-4 trial was certainly not free from its share of scrutiny.
- Subjects
CLINICAL trials; CLINICAL drug trials; PHYSICIAN practice patterns; THERAPEUTICS; BLOOD coagulation factor X
- Publication
Annals of Pharmacotherapy, 2019, Vol 53, Issue 11, p1167
- ISSN
1060-0280
- Publication type
letter
- DOI
10.1177/1060028019855160